C4 Therapeutics, Inc. - Common Stock (CCCC)

C4 Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to target and degrade disease-causing proteins, particularly in cancer treatment

By leveraging its proprietary technology platform, C4 Therapeutics aims to create highly selective and effective drug candidates that can modulate the protein environment within cells, offering new hope for patients with various types of cancer and other serious diseases. The company's approach is centered on the principle of targeted protein degradation, which has the potential to transform the therapeutic landscape by eliminating harmful proteins rather than merely inhibiting them.